| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 01/28/2003 | US6511982 Synergistic mixture of acetaminophen and buspirone |
| 01/28/2003 | US6511965 Ether type lipid A 1-carboxylic acid analogs |
| 01/28/2003 | US6511825 Cell signaling polypeptides and nucleic acids |
| 01/28/2003 | US6511807 Carbohydrate ligand that specifically binds to a leczyme; nucleic acid sequence encoding a nonclassical MHC class I heavy chain; ability to associate with a beta 2 microglobulin; major histocompatibility complex transplantation molecules |
| 01/28/2003 | US6511648 Vitronectin receptor antagonist pharmaceuticals |
| 01/28/2003 | CA2318432C The use of isolated domains of type iv collagen to modify cell and tissue interactions |
| 01/27/2003 | WO2002010127A1 Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia |
| 01/27/2003 | CA2417427A1 Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia |
| 01/27/2003 | CA2391642A1 Identification and use of molecules implicated in pain |
| 01/27/2003 | CA2391112A1 Identification and use of molecules implicated in pain |
| 01/24/2003 | WO2002010145A1 Urethane derivatives |
| 01/24/2003 | CA2417268A1 Urethane derivatives |
| 01/24/2003 | CA2394209A1 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| 01/23/2003 | WO2003006996A2 Natural ligand of gpcr chemr23 and uses thereof |
| 01/23/2003 | WO2003006645A2 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | WO2003006500A1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 01/23/2003 | WO2003006491A2 Peptide-based compounds for targeting intergin receptors |
| 01/23/2003 | WO2003006478A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | WO2003006460A1 L-ascorbic acid-2-o-maleic acid-a-tocopherol diester 1-propanol adduct and process for producing the same |
| 01/23/2003 | WO2003006459A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | WO2003006451A1 4-phenylpyran-2-one derivatives |
| 01/23/2003 | WO2003006438A1 Benzimidazole derivatives for treating microglia-activation associated diseases such as inflammatory, allergic, infectious or autoimmune diseases |
| 01/23/2003 | WO2003006437A1 Imidazole derivatives as adenosine deaminase inhibitors |
| 01/23/2003 | WO2003006425A2 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | WO2003006424A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | WO2003006104A2 Lymphatic endothelial cells materials and methods |
| 01/23/2003 | WO2003006057A1 Composition and method for the treatment of disease |
| 01/23/2003 | WO2003006048A1 Combination of chips (chemotaxis inhibiting protein from staphylococcus aureus)-based compounds |
| 01/23/2003 | WO2003006036A2 Herbal formulation |
| 01/23/2003 | WO2003006034A2 Herbal formulation |
| 01/23/2003 | WO2003006026A1 Combinations for the treatment of inflammatory disorders |
| 01/23/2003 | WO2003006016A2 Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury |
| 01/23/2003 | WO2003006010A1 Aerosol formulations of δ8 tetrahydrocannabinol |
| 01/23/2003 | WO2003006003A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 01/23/2003 | WO2003005999A2 Methods of treating cytokine mediated diseases |
| 01/23/2003 | WO2003005971A2 Tetracycline compounds having target therapeutic activities |
| 01/23/2003 | WO2003005965A2 Modulators of ceramidase and methods of use based thereon |
| 01/23/2003 | WO2003005960A2 Novel bicyclic and tricyclic cannabinoids |
| 01/23/2003 | WO2003005956A2 A hydroxamic acid thrombospondin peptide analog that inhibits aggrecanase activity |
| 01/23/2003 | WO2003005953A2 Viral proteins capable of binding lar |
| 01/23/2003 | WO2002083159B1 Palliative effects of morinda citrifolia oil and juice |
| 01/23/2003 | WO2002072827A9 Traf3-binding b cell-specific receptor |
| 01/23/2003 | WO2002070676A3 Use of protein histidine phosphatase |
| 01/23/2003 | WO2002066978A3 Detection of compounds that modulate inflammatory responses |
| 01/23/2003 | WO2002056790A3 Delivery of therapeutic capable agents |
| 01/23/2003 | WO2002050066A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/23/2003 | WO2002046171A3 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002026265A3 Pegylated interleukin-10 |
| 01/23/2003 | WO2002022559A3 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 01/23/2003 | WO2002020619A3 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 01/23/2003 | WO2002010405A3 A human disintegrin protein |
| 01/23/2003 | WO2002010363A3 Protein phosphatases |
| 01/23/2003 | WO2002008177A2 N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives |
| 01/23/2003 | WO2001083782A3 Novel proteases |
| 01/23/2003 | US20030018197 Administering a therapeutically effective amount of a pyrrazole sulfide or ether compound to treat the human immunodeficiency virus infection |
| 01/23/2003 | US20030018194 New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents |
| 01/23/2003 | US20030018193 Beta-alanine derivatives and their use as receptor anatgonists |
| 01/23/2003 | US20030018181 Antiinflammatory agents; culturing; isolation of fusion protein |
| 01/23/2003 | US20030018180 Secreted protein HFEAF41 |
| 01/23/2003 | US20030018165 Uses of suppressive macrophage activation factors |
| 01/23/2003 | US20030018077 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease |
| 01/23/2003 | US20030018064 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists |
| 01/23/2003 | US20030018060 Therapeutic methods and compositions involving isoflavones |
| 01/23/2003 | US20030018058 3-aminopyrazole inhibitors of cyclin dependent kinases |
| 01/23/2003 | US20030018041 Spiroindene and spiroindane compounds |
| 01/23/2003 | US20030018040 Tumor necrosis factor antagonist; side effect reduction;antiinflammatory agents |
| 01/23/2003 | US20030018032 Bicyclic imidazo-3-yl-amine derivatives |
| 01/23/2003 | US20030018016 Cell adhesion inhibitors |
| 01/23/2003 | US20030018013 Cardiovascular disorders; antilipemic agents; Alzheimer's disease |
| 01/23/2003 | US20030018005 Autoimmune disease; antiinflammatory agents; antiallergens; rheumatic diseases; antitumor agents |
| 01/23/2003 | US20030017977 Methods of treating inflammatory skin diseases |
| 01/23/2003 | US20030017965 Methods for treating certain diseases using naaladase inhibitors |
| 01/23/2003 | US20030017617 Mammalian receptor proteins; related reagents and methods |
| 01/23/2003 | US20030017548 Proteins for use in treatment of gastrointestinal disorders |
| 01/23/2003 | US20030017527 Human vanilloid receptor-like proteins |
| 01/23/2003 | US20030017207 Compositions and methods for treating vulvovaginitis and vaginosis |
| 01/23/2003 | US20030017166 Combination preparation for the therapy of immunological diseases |
| 01/23/2003 | US20030017157 Endothelial cell expression patterns |
| 01/23/2003 | US20030017155 Treating a condition characterized by activation of the inflammatory cytokine cascade |
| 01/23/2003 | US20030017145 Treating subjects suffering from herpes virus infections, acquired immunodeficiency syndrome, and hepatitis C infections by administering a compound effective to inhibit the production or release of the ROMs. |
| 01/23/2003 | US20030017141 Treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject; isolating a stromal-cell-derived fugetactic agent |
| 01/23/2003 | US20030017120 Delivery of erectile dysfunction drugs through an inhalation route |
| 01/23/2003 | US20030017119 Aerosol comprises particles comprising at least 10 percent by weight of an opioid, and wherein the opioid is not heroin; opiods include morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, etc. |
| 01/23/2003 | US20030017118 An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of an antipsychotic such as olanzapine, trifluoperazine, haloperidol, loxapine, clozapine, quetiapine, promazine, etc. |
| 01/23/2003 | US20030017117 Delivery of analgesics through an inhalation route |
| 01/23/2003 | US20030017116 Delivery of sedative-hypnotics through an inhalation route |
| 01/23/2003 | US20030017115 Aerosol comprises particles comprising at least 10 percent by weight of a drug ester. |
| 01/23/2003 | US20030017114 Aerosol comprises particles of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine. |
| 01/23/2003 | US20030015190 Delivery of compounds for the treatment of migraine through an inhalation route |
| 01/23/2003 | US20030015189 Delivery of antihistamines through an inhalation route |
| 01/23/2003 | CA2821544A1 Use of follistatin for the treatment of pulmonary fibrosis and fibrosis associated with inflammatory bowel disease |
| 01/23/2003 | CA2453566A1 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | CA2453470A1 Use of follistatin for the treatment of hepatic fibrogenesis |
| 01/23/2003 | CA2453399A1 Combinations for the treatment of inflammatory disorders |
| 01/23/2003 | CA2453389A1 Aerosol formulations of .delta.8 tetrahydrocannabinol |
| 01/23/2003 | CA2453362A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | CA2453346A1 A hydroxamic acid thrombospondin peptide analog that inhibits aggrecanase activity |
| 01/23/2003 | CA2453161A1 Lymphatic endothelial cells materials and methods |
| 01/23/2003 | CA2453147A1 Methods of treating cytokine mediated diseases |